March 2022 – Gator Psychiatry

Tweet by Tom Insel, MD on Twitter

Tom Insel, MD ⁦‪@thomasinselmd‬⁩ The crisis of care is not just lack of access but lack of engagement. The majority of people with #mentalillness are not in treatment. And the 40% who are in treatment receive low-quality care, so only 1/3 of those in care will experience the full benefit. We must do better. pic.twitter.com/b8MkXuoqG0Continue reading “Tweet by Tom Insel, MD on Twitter”

Tweet by STAT on Twitter

STAT ⁦‪@statnews‬⁩ The pharmaceutical industry is still struggling to tackle Alzheimer’s disease. Now, health tech companies are now trying to take a crack at it. buff.ly/3uK6mIa 3/31/22, 7:00 AM

Resource articles on RX of PMDD

The Biggs article includes the Daily Record Scale which is use in treatment studies. All sources comment the mechanism of RX is specific to the SSRI as opposed to antidepressants and cite a) immediate clinical effect in PMDD b) lack of effect from non-SRI antidepressants. Occasional use of the SSRI (ie symptoms onset ) asContinue reading “Resource articles on RX of PMDD”

Tweet by Vandenbroucke lab Alzheimer’s graphic pathology’s

Vandenbroucke lab ⁦‪@Vdb_lab‬⁩ Alzheimer’s disease has an alarming increasing prevalence. We urgently need to improve our understanding behind the pathogenesis. In ⁦‪@FrontImmunol‬⁩ we now give a comprehensive overview on how systemic and intestinal inflammatory processes may affect brain pathology. pic.twitter.com/V8FN8ibW9l 3/24/22, 7:03 AM

Tweet by JAMA Psychiatry on Twitter

JAMA Psychiatry ⁦‪@JAMAPsych‬⁩ This systematic review and meta-analysis explored the outcomes and moderators of psychological interventions delivered by nonspecialists for #depression in low- and middle-income countries. ja.ma/355nlMp #globalhealth #mentalhealth 3/24/22, 6:00 PM